Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

Blood blood.2024025624.

https://doi.org/10.1182/blood.2024025624

Published: 2024

Includes: Supplemental data

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Blood (2024) 144 (Supplement 1): 7039.

https://doi.org/10.1182/blood-2024-210376

Published: 2024

Journal Articles

Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression

Jon Thorir Oskarsson, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, Andri Olafsson, Elias Eythorsson, Asbjorn Jonsson, Brynjar Vidarsson, Pall T. Onundarson, Bjarni Agnarsson, Margret Sigurdardottir, Ingunn Thorsteinsdottir, Isleifur Olafsson, Stephen J. Harding, Brian G.M. Durie, Thorvardur Jon Love, Sigurdur Y Kristinsson

Blood (2024) 144 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2024-200422

Published: 2024

Journal Articles

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Hira Mian, Carlyn Rose Tan, Sireesha Asoori, Rakesh Popat, Nadine Abdallah, Saurabh Chhabra, Ricardo D. Parrondo, Gregory R Pond, Thomas Martin, Brian G.M. Durie, Yi Lin

Blood (2024) 144 (Supplement 1): 704.

https://doi.org/10.1182/blood-2024-200877

Published: 2024

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Blood (2024) 144 (Supplement 1): 7012.

https://doi.org/10.1182/blood-2024-200679

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G.M. Durie, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2024-208341

Published: 2024

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study

Blood (2022) 140 (Supplement 1): 2338–2340.

https://doi.org/10.1182/blood-2022-164758

Published: 2022

Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4349–4351.

https://doi.org/10.1182/blood-2022-166609

Published: 2022

Journal Articles

Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Blood (2022) 140 (Supplement 1): 261–263.

https://doi.org/10.1182/blood-2022-157138

Published: 2022

Journal Articles

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Sridurga Mithraprabhu, John Reynolds, Rose Turner, Hang Quach, Noemi Horvath, Ian H Kerridge, Flora Yuen, Tiffany Khong, Brian G.M. Durie, Andrew Spencer

Blood (2022) 140 (Supplement 1): 9933–9934.

https://doi.org/10.1182/blood-2022-171053

Published: 2022

Journal Articles

Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort

Blood (2022) 140 (Supplement 1): 9923–9924.

https://doi.org/10.1182/blood-2022-168690

Published: 2022

Journal Articles

Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do

Blood (2022) 140 (Supplement 1): 256–258.

https://doi.org/10.1182/blood-2022-163169

Published: 2022

Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

Blood (2022) 140 (Supplement 1): 1830–1832.

https://doi.org/10.1182/blood-2022-168930

Published: 2022

Journal Articles

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

Brian G.M. Durie, Annette Lam, Mai Ngo, Huiling Pei, Eric M. Ammann

Blood (2022) 140 (Supplement 1): 10009–10010.

https://doi.org/10.1182/blood-2022-165591

Published: 2022

Journal Articles

Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort

Blood (2022) 140 (Supplement 1): 266–267.

https://doi.org/10.1182/blood-2022-170166

Published: 2022

Journal Articles

Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Blood (2022) 140 (Supplement 1): 10108–10109.

https://doi.org/10.1182/blood-2022-170623

Published: 2022

Journal Articles

Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study

Blood (2022) 140 (Supplement 1): 10031–10032.

https://doi.org/10.1182/blood-2022-169393

Published: 2022

Journal Articles

Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study

Blood (2022) 140 (Supplement 1): 10024–10026.

https://doi.org/10.1182/blood-2022-168070

Published: 2022

NARROW

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort

Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort

Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study

Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only